The Omicron variant of COVID-19 was predominant during Moderna’s pediatric trial, and the drugmaker said two doses were around 38% effective in preventing infections in 2 to 5 year olds and 44% effective for children 6 months to under 2 years old.
A rival shot made by Pfizer Inc and Germany’s BioNTech SE is authorized for use in children 5 and older. But their trial results for 2- to 4-year olds showed a weaker immune response than in adults, forcing the trial to be extended to test a third dose. Results are expected in April. The dose size tested was 25 micrograms – a quarter of the dose that adults receive for each of their first two shots.
Moderna’s vaccine is approved by the FDA for use in adults 18 and older. But it has yet to be approved for 6 to 17 year olds in the United States despite gaining approval for that age group in Australia, Canada and the European Union. The United Kingdom and Switzerland have allowed the vaccine to be used in 12-17 year olds.
Small children do not get severe Covid-19 symptoms. Moderna is following the money.
Have you ever wonder how you can start a trade Investments? and be profitable trader Well, I'm happy to share an educator page with you. Go follow him now on GAODwyer01 and be financially stable with his amazing trading software